Development of novel synthetic lung surfactants for treatment of respiratory distress syndrome
Author: Basabe Burgos, Oihana
Date: 2020-03-20
Location: Erna Möllersalen, Neo, floor 5, Blickagången 16, Karolinska Institutet, Huddinge
Time: 09.30
Department: Inst för neurobiologi, vårdvetenskap och samhälle / Dept of Neurobiology, Care Sciences and Society
View/ Open:
Thesis (1.307Mb)
Abstract
Pulmonary surfactant is a complex mixture of lipids and specific proteins found in the alveoli
and its main role is to reduce the surface tension of the alveolar air/water interface, thereby
preventing lung collapse. Lack of pulmonary surfactant in premature babies results in lethal
respiratory distress syndrome (RDS), which is today treated with surfactant replacement
therapy, i.e. delivery of pulmonary surfactant extracted from animal lungs into the airways.
Despite the effectiveness of surfactant replacement therapy, it has several limitations:
pronounced batch to batch variability, risk of disease transmission, and expensive source
material and production procedures. Moreover, RDS secondary to surfactant inhibition in
adults (ARDS) has turned out to be difficult to treat with existing natural derived surfactant
preparations, probably for a combination of reasons, such as limited supply and sensitivity to
inhibition. The development of synthetic pulmonary surfactants is a tempting solution that
could overcome these limitations, but in spite of more than 30 years of development work,
there still no synthetic surfactant in clinical use.
The two surfactant proteins B (SP-B) and C (SP-C) that are present in natural derived surfactants are difficult to produce or replicate and the lipid composition of natural surfactants is very complex. As a result, the development of simple lipid compositions and surfactant protein analogues that can reproduce the activity of animal derived surfactants is not trivial. In this thesis, we designed surfactant protein analogues and tested their activities in animal models of neonatal RDS and ARDS. We investigated the importance of intramolecular disulfide bonds in an SP-B analogue, and we improved the recombinant production of the SP-C analogue SPC33Leu. Artificial surfactant based on recombinant SP-C33Leu improved lung mechanics in an RDS model and enhanced lung function and reduced inflammation in an ARDS model.
Finally, we investigated the novel concept of creating surfactant protein analogues that combine both SP-B and SP-C activities in one polypeptide. We designed and recombinantly produced polypeptides that fuse an SP-B analogue and an SP-C analogue - Combo peptides - and tested mixtures of these analogues with two phospholipid species in an RDS model ventilated without stabilizing end expiration pressures in the lung. Mixtures containing low amounts of Combo peptides improve lung function in a similar manner as a clinically used natural derived surfactant. The Combo peptide approach can deliver simple synthetic surfactants that match currently used natural preparations and can be produced efficiently.
The two surfactant proteins B (SP-B) and C (SP-C) that are present in natural derived surfactants are difficult to produce or replicate and the lipid composition of natural surfactants is very complex. As a result, the development of simple lipid compositions and surfactant protein analogues that can reproduce the activity of animal derived surfactants is not trivial. In this thesis, we designed surfactant protein analogues and tested their activities in animal models of neonatal RDS and ARDS. We investigated the importance of intramolecular disulfide bonds in an SP-B analogue, and we improved the recombinant production of the SP-C analogue SPC33Leu. Artificial surfactant based on recombinant SP-C33Leu improved lung mechanics in an RDS model and enhanced lung function and reduced inflammation in an ARDS model.
Finally, we investigated the novel concept of creating surfactant protein analogues that combine both SP-B and SP-C activities in one polypeptide. We designed and recombinantly produced polypeptides that fuse an SP-B analogue and an SP-C analogue - Combo peptides - and tested mixtures of these analogues with two phospholipid species in an RDS model ventilated without stabilizing end expiration pressures in the lung. Mixtures containing low amounts of Combo peptides improve lung function in a similar manner as a clinically used natural derived surfactant. The Combo peptide approach can deliver simple synthetic surfactants that match currently used natural preparations and can be produced efficiently.
List of papers:
I. Basabe-Burgos, O., Johansson, J. and Curstedt, T. Disulphide bridges in surfactant protein B analogues affect their activity in synthetic surfactant preparations. Neonatology. 115, 134-141 (2019).
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Basabe-Burgos, O., Zebialowicz Ahlstrom, J., Mikolka, P., Landreh, M., Johansson, J., Curstedt, T. and Rising, A. Efficient delipidation of a recombinant lung surfactant lipopeptide analogue by liquid-gel chromatography. PLoS One. 14, e0226072 (2019).
Fulltext (DOI)
Pubmed
III. Zebialowicz Ahlstrom, J., Massaro, F., Mikolka, P., Feinstein, R., Perchiazzi, G., Basabe-Burgos, O., Curstedt, T., Larsson, A., Johansson, J. and Rising, A. Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits. Respir Res. 20, 245 (2019).
Fulltext (DOI)
Pubmed
View record in Web of Science®
IV. Basabe-Burgos, O., Landreh, M., Rising, A., Curstedt, T. and Johansson, J. Treatment of respiratory distress syndrome with synthetic surfactants containing phospholipids and single polypeptide analogues that combine features of SP-B and SP-C. [Manuscript]
I. Basabe-Burgos, O., Johansson, J. and Curstedt, T. Disulphide bridges in surfactant protein B analogues affect their activity in synthetic surfactant preparations. Neonatology. 115, 134-141 (2019).
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Basabe-Burgos, O., Zebialowicz Ahlstrom, J., Mikolka, P., Landreh, M., Johansson, J., Curstedt, T. and Rising, A. Efficient delipidation of a recombinant lung surfactant lipopeptide analogue by liquid-gel chromatography. PLoS One. 14, e0226072 (2019).
Fulltext (DOI)
Pubmed
III. Zebialowicz Ahlstrom, J., Massaro, F., Mikolka, P., Feinstein, R., Perchiazzi, G., Basabe-Burgos, O., Curstedt, T., Larsson, A., Johansson, J. and Rising, A. Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits. Respir Res. 20, 245 (2019).
Fulltext (DOI)
Pubmed
View record in Web of Science®
IV. Basabe-Burgos, O., Landreh, M., Rising, A., Curstedt, T. and Johansson, J. Treatment of respiratory distress syndrome with synthetic surfactants containing phospholipids and single polypeptide analogues that combine features of SP-B and SP-C. [Manuscript]
Institution: Karolinska Institutet
Supervisor: Johansson, Jan
Co-supervisor: Rising, Anna
Issue date: 2020-02-26
Rights:
Publication year: 2020
ISBN: 978-91-7831-738-7
Statistics
Total Visits
Views | |
---|---|
Development ... | 1460 |
Total Visits Per Month
August 2020 | September 2020 | October 2020 | November 2020 | December 2020 | January 2021 | February 2021 | |
---|---|---|---|---|---|---|---|
Development ... | 41 | 49 | 21 | 24 | 24 | 26 | 14 |
File Visits
Views | |
---|---|
Thesis_Oihana_Basabe_Burgos.pdf | 458 |
Thesis_Oihana_BasabeBurgos.pdf | 2 |
Top country views
Views | |
---|---|
Sweden | 695 |
United States | 308 |
Germany | 55 |
China | 42 |
Bulgaria | 34 |
Russia | 32 |
Denmark | 26 |
India | 22 |
United Kingdom | 21 |
Turkey | 18 |
Top cities views
Views | |
---|---|
Karlstad | 640 |
Ashburn | 37 |
Sofia | 26 |
Copenhagen | 21 |
Moscow | 14 |
Stockholm | 11 |
Sydney | 11 |
Beijing | 9 |
Huddinge | 8 |
Ankara | 7 |